Clinical Trial

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 17, 2025 (before its estimated April 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The combined pertussis, diphtheria and tetanus vaccine, the first vaccine to be included in the Expanded Programme of Immunization(EPI) of World Health Organization(WHO), has played an important role in the prevention and control of these three infectious diseases. The (diphtheria，tetanus and acellular pertussis combined vaccine，DTaP) vaccine was successfully developed in China in 1993, and its safety and serological effects were confirmed by the observation of human safety, with mild vaccination reactions and good immunization effects.The (Diphtheria-tetanus-component acellular pertussis vaccine, DTcP) vaccine is suitable for immunization against pertussis, diphtheria and tetanus infections in people between 2 and 24 months of age.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-07-10; most recent amendment 2025-03-14.
Status change: Recruiting → Active, Not Recruiting 2024-03-24
Status change: Not Yet Recruiting → Recruiting 2023-08-12
Trial Details
NCT Number NCT05951725
Lead Sponsor CanSino Biologics Inc.
Conditions Diphtheria, Tetanus and Acellular Pertussis
Enrollment 2,520 participants
Start Date 2023-08-11
Primary Completion 2025-04-01 (estimated)
Study Completion 2025-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-17